Department of Emergency Internal Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3919-3924. doi: 10.26355/eurrev_201806_15277.
The morbidity of atrial fibrillation (AF) is 1%-2% in clinic. Radiofrequency catheter ablation (RFCA) is a type of radical interventional therapy for AF, whereas it may lead to a hypercoagulable state. This study evaluated platelet particle CD62P and platelet activation biomarker GP IIb/IIIa expressions in AF patients treated by RFCA, and aimed to analyze their relationships with the hypercoagulable state after RFCA.
A total of 60 AF patients received RFCA in our hospital were enrolled. The patients were divided into group A as hypercoagulable state group and group B as non-hypercoagulable group. Healthy volunteers were selected as normal control. Serum D-Dimer, parathyroid activity index 1 (PAI-1), and tissue plasminogen activator (t-PA) content were tested by using enzyme-linked immunosorbent assay (ELISA), while peripheral CD62P and GP IIb/IIIa expressions were detected by using flow cytometry before, after, and seven days after RFCA.
D-Dimer and PAI-1 levels increased, while t-PA reduced in group A compared with that in group B and control (p<0.05). D-Dimer and t-PA contents gradually elevated, whereas t-PA level gradually declined in group A before, after, and seven days after RFCA (p<0.05). Serum CD62P and GP IIb/IIIa expressions in group A were significantly higher compared to that in group B and control (p<0.05). CD62P and GP IIb/IIIa levels were significantly higher seven days after RFCA compared with immediate after RFCA in group A (p<0.05). CD62P showed a positive correlation with GP IIb/IIIa in hypercoagulable state patients after RFCA (p<0.05).
AF patient may appear in hypercoagulable state after RFCA. CD62P and GP IIb/IIIa significantly increased and exhibited a positive correlation.
临床中心律失常（AF）的发病率为 1%-2%。射频导管消融（RFCA）是治疗 AF 的一种根治性介入治疗方法，但可能导致高凝状态。本研究评估了接受 RFCA 治疗的 AF 患者血小板颗粒 CD62P 和血小板活化生物标志物 GP IIb/IIIa 的表达，并旨在分析它们与 RFCA 后高凝状态的关系。
共纳入我院接受 RFCA 的 60 例 AF 患者。患者分为 A 组（高凝状态组）和 B 组（非高凝状态组）。选择健康志愿者作为正常对照组。采用酶联免疫吸附试验（ELISA）检测血清 D-二聚体、甲状旁腺活性指数 1（PAI-1）和组织型纤溶酶原激活物（t-PA）含量，采用流式细胞术检测外周血 CD62P 和 GP IIb/IIIa 表达，分别在 RFCA 前、后和 7 天检测。
与 B 组和对照组相比，A 组 D-二聚体和 PAI-1 水平升高，t-PA 水平降低（p<0.05）。A 组 D-Dimer 和 t-PA 含量逐渐升高，而 t-PA 水平在 RFCA 前后 7 天逐渐下降（p<0.05）。与 B 组和对照组相比，A 组血清 CD62P 和 GP IIb/IIIa 表达明显升高（p<0.05）。与 RFCA 后即刻相比，A 组在 RFCA 后 7 天的 CD62P 和 GP IIb/IIIa 水平明显升高（p<0.05）。RFCA 后高凝状态患者的 CD62P 与 GP IIb/IIIa 呈正相关（p<0.05）。
AF 患者在 RFCA 后可能出现高凝状态。CD62P 和 GP IIb/IIIa 明显增加并呈正相关。
